1
|
Kim D, Elf P, Nilsson F, Hedenqvist MS, Larsson A. In-Depth Understanding of the Effect of the Distribution of Substituents on the Morphology and Physical Properties of Ethylcellulose: Molecular Dynamics Simulations Insights. Biomacromolecules 2024; 25:4046-4062. [PMID: 38913613 PMCID: PMC11238332 DOI: 10.1021/acs.biomac.4c00166] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/05/2024] [Revised: 06/04/2024] [Accepted: 06/05/2024] [Indexed: 06/26/2024]
Abstract
Ethylcellulose (EC) is a crucial cellulose derivative with widespread applications, particularly in the pharmaceutical industry, where precise property adjustments through chemical modification are imperative. The degree of substitution (DS) and the localization of substituents along the cellulose chains are pivotal factors in this process. However, the impact of the substituent location within the repeating unit of EC remains unexplored. To address this gap, we conducted molecular dynamics simulations on amorphous EC, comparing randomly and uniformly substituted ethyl groups in the repeating units. This comprehensive study of pairwise interactions revealed significant differences in intramolecular and intermolecular hydrogen-bonding capabilities, depending on whether the hydroxyl groups were substituted at C2, C3, or C6. While our simulations demonstrated that substituent localization in the repeating unit influenced the density, number of hydrogen bonds, and conformations, the DS emerged as the dominant determinant. This insight led us to propose and validate a hypothesis: a straightforward linear function using the properties of uniform models and molar fractions can predict the properties of randomly substituted EC with a given DS. This innovative approach is anticipated to contribute to the selection of cellulose derivatives with desirable properties for the pharmaceutical industry and new applications in other fields.
Collapse
Affiliation(s)
- Donghyun Kim
- Applied
Chemistry, Department of Chemistry and Chemical Engineering, Chalmers University of Technology, SE-412 96 Gothenburg, Sweden
- FibRe
Centre for Lignocellulose-based Thermoplastics, Department of Chemistry
and Chemical Engineering, Chalmers University
of Technology, SE-412 96 Gothenburg, Sweden
- Wallenberg
Wood Science Center, Chalmers University
of Technology, SE-412 96 Gothenburg, Sweden
| | - Patric Elf
- Department
of Fibre and Polymer Technology, School of Engineering Sciences in
Chemistry, Biotechnology and Health, KTH
Royal Institute of Technology, SE-100 44 Stockholm, Sweden
- FibRe
Vinnova competence center, KTH Royal Institute
of Technology, SE-100 44 Stockholm, Sweden
| | - Fritjof Nilsson
- Department
of Fibre and Polymer Technology, School of Engineering Sciences in
Chemistry, Biotechnology and Health, KTH
Royal Institute of Technology, SE-100 44 Stockholm, Sweden
- FibRe
Vinnova competence center, KTH Royal Institute
of Technology, SE-100 44 Stockholm, Sweden
- FSCN
research centre, Mid Sweden University, 85170 Sundsvall, Sweden
| | - Mikael S. Hedenqvist
- Department
of Fibre and Polymer Technology, School of Engineering Sciences in
Chemistry, Biotechnology and Health, KTH
Royal Institute of Technology, SE-100 44 Stockholm, Sweden
- FibRe
Vinnova competence center, KTH Royal Institute
of Technology, SE-100 44 Stockholm, Sweden
- Wallenberg
Wood Science Center, KTH Royal Institute
of Technology, SE-100 44 Stockholm, Sweden
| | - Anette Larsson
- Applied
Chemistry, Department of Chemistry and Chemical Engineering, Chalmers University of Technology, SE-412 96 Gothenburg, Sweden
- FibRe
Centre for Lignocellulose-based Thermoplastics, Department of Chemistry
and Chemical Engineering, Chalmers University
of Technology, SE-412 96 Gothenburg, Sweden
- Wallenberg
Wood Science Center, Chalmers University
of Technology, SE-412 96 Gothenburg, Sweden
| |
Collapse
|
2
|
Mora-Castaño G, Millán-Jiménez M, Niederquell A, Schönenberger M, Shojaie F, Kuentz M, Caraballo I. Amorphous solid dispersion of a binary formulation with felodipine and HPMC for 3D printed floating tablets. Int J Pharm 2024; 658:124215. [PMID: 38740104 DOI: 10.1016/j.ijpharm.2024.124215] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2024] [Revised: 04/19/2024] [Accepted: 05/07/2024] [Indexed: 05/16/2024]
Abstract
This study focuses on the combination of three-dimensional printing (3DP) and amorphous solid dispersion (ASD) technologies for the manufacturing of gastroretentive floating tablets. Employing hot melt extrusion (HME) and fused deposition modeling (FDM), the study investigates the development of drug-loaded filaments and 3D printed (3DP) tablets containing felodipine as model drug and hydroxypropyl methylcellulose (HPMC) as the polymeric carrier. Prior to fabrication, solubility parameter estimation and molecular dynamics simulations were applied to predict drug-polymer interactions, which are crucial for ASD formation. Physical bulk and surface characterization complemented the quality control of both drug-loaded filaments and 3DP tablets. The analysis confirmed a successful amorphous dispersion of felodipine within the polymeric matrix. Furthermore, the low infill percentage and enclosed design of the 3DP tablet allowed for obtaining low-density systems. This structure resulted in buoyancy during the entire drug release process until a complete dissolution of the 3DP tablets (more than 8 h) was attained. The particular design made it possible for a single polymer to achieve a zero-order controlled release of the drug, which is considered the ideal kinetics for a gastroretentive system. Accordingly, this study can be seen as an advancement in ASD formulation for 3DP technology within pharmaceutics.
Collapse
Affiliation(s)
- Gloria Mora-Castaño
- Department of Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, Universidad de Sevilla, 41012 Seville, Spain
| | - Mónica Millán-Jiménez
- Department of Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, Universidad de Sevilla, 41012 Seville, Spain.
| | - Andreas Niederquell
- School of Life Sciences, University of Applied Sciences and Arts Northwestern Switzerland, CH 4132 Muttenz, Switzerland
| | - Monica Schönenberger
- University of Basel, Swiss Nanoscience Institute, Nano Imaging Lab, Klingelbergstrasse 82, 4056 Basel, Switzerland
| | - Fatemeh Shojaie
- Department of Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, Universidad de Sevilla, 41012 Seville, Spain
| | - Martin Kuentz
- School of Life Sciences, University of Applied Sciences and Arts Northwestern Switzerland, CH 4132 Muttenz, Switzerland
| | - Isidoro Caraballo
- Department of Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, Universidad de Sevilla, 41012 Seville, Spain
| |
Collapse
|
3
|
Olsson M, Govender R, Diaz A, Holler M, Menzel A, Abrahmsén-Alami S, Sadd M, Larsson A, Matic A, Liebi M. Multiscale X-ray imaging and characterisation of pharmaceutical dosage forms. Int J Pharm 2023:123200. [PMID: 37414373 DOI: 10.1016/j.ijpharm.2023.123200] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/01/2023] [Revised: 06/30/2023] [Accepted: 07/01/2023] [Indexed: 07/08/2023]
Abstract
A correlative, multiscale imaging methodology for visualising and quantifying the morphology of solid dosage forms by combining ptychographic X-ray computed nanotomography (PXCT) and scanning small- and wide-angle X-ray scattering (S/WAXS) is presented. The methodology presents a workflow for multiscale analysis, where structures are characterised from the nanometre to millimetre regime. Here, the method is demonstrated by characterising a hot-melt extruded, partly crystalline, solid dispersion of carbamazepine in ethyl cellulose. Characterisation of the morphology and solid-state phase of the drug in solid dosage forms is central as this affects the performance of the final formulation. The 3D morphology was visualised at a resolution of 80 nm over an extended volume through PXCT, revealing an oriented structure of crystalline drug domains aligned in the direction of extrusion. Scanning S/WAXS, showed that the nanostructure is similar over the cross section of the extruded filament, with minor radial changes in domain sizes and degree of orientation. The polymorphic forms of carbamazepine were qualified with WAXS, showing a heterogeneous distribution of the metastable forms I and II. This demonstrates the methodology for multiscale structural characterization and imaging to enable a better understanding of the relationships between morphology, performance, and processing conditions of solid dosage forms.
Collapse
Affiliation(s)
- Martina Olsson
- Department of Physics, Chalmers University of Technology, SE-412 96, Gothenburg, Sweden
| | - Rydvikha Govender
- Oral Product Development, Pharmaceutical Technology and Development, Operations, AstraZeneca, SE-43183 Gothenburg, Sweden; Department of Chemistry and Chemical Engineering, Chalmers University of Technology, SE-412 96, Gothenburg, Sweden
| | - Ana Diaz
- Photon Science Division, Paul Scherrer Institut, Villigen PSI, 5232, Switzerland
| | - Mirko Holler
- Photon Science Division, Paul Scherrer Institut, Villigen PSI, 5232, Switzerland
| | - Andreas Menzel
- Photon Science Division, Paul Scherrer Institut, Villigen PSI, 5232, Switzerland
| | - Susanna Abrahmsén-Alami
- Innovation Strategies & External Liaison, Pharmaceutical Technology & Development, Operations, AstraZeneca, SE-43183 Gothenburg, Sweden
| | - Matthew Sadd
- Department of Physics, Chalmers University of Technology, SE-412 96, Gothenburg, Sweden
| | - Anette Larsson
- Department of Chemistry and Chemical Engineering, Chalmers University of Technology, SE-412 96, Gothenburg, Sweden; FibRe-Centre for Lignocellulose-based Thermoplastics, Department of Chemistry and Chemical Engineering, Chalmers University of Technology, SE-412 96 Gothenburg, Sweden
| | - Aleksandar Matic
- Department of Physics, Chalmers University of Technology, SE-412 96, Gothenburg, Sweden; FibRe-Centre for Lignocellulose-based Thermoplastics, Department of Chemistry and Chemical Engineering, Chalmers University of Technology, SE-412 96 Gothenburg, Sweden; Wallenberg Wood Science Center, Chalmers University of Technology, SE-412 96 Gothenburg, Sweden
| | - Marianne Liebi
- Department of Physics, Chalmers University of Technology, SE-412 96, Gothenburg, Sweden; Photon Science Division, Paul Scherrer Institut, Villigen PSI, 5232, Switzerland; Institute of Materials, École Polytechnique Fédérale de Lausanne (EPFL), Lausanne, 1015 Switzerland
| |
Collapse
|
4
|
Gorkem Buyukgoz G, Kossor CG, Ji S, Guvendiren M, Davé RN. Dose Titration of Solid Dosage Forms via FDM 3D-Printed Mini-Tablets. Pharmaceutics 2022; 14:2305. [PMID: 36365124 PMCID: PMC9695869 DOI: 10.3390/pharmaceutics14112305] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/29/2022] [Revised: 10/17/2022] [Accepted: 10/25/2022] [Indexed: 07/27/2024] Open
Abstract
The robustness of 3D-printed mini-tablets as a platform to administer milligram dosages, intended for age-specific therapy, without the need of tablet splitting while maintaining similar release profiles, was investigated. Griseofulvin, as a model poorly water-soluble drug, and hydroxypropyl cellulose along with Kollicoat Protect as polymers were used to prepare filaments at 1-20% drug concentrations via hot-melt extrusion (HME). Higher drug concentrations served for testing the feasibility of a reduced number of mini-tablets to be administered. A reliable dose titration in the range 0.19-3.91 mg at a high accuracy (R2 of 0.999) was achieved through composite unit (multi-unit) mini-tablets. All mini-tablets produced had excellent content uniformity and their label claim values were within the acceptable range, proving that HME processing followed by 3D printing promotes content uniformity even for mini-tablets containing low drug doses (0.19 mg). Remarkably, the proposed approach allowed achieving similar drug release profiles via composite unit mini-tablets as well as single mini-tablets at high drug concentrations. In contrast, split tablets demonstrated different release behaviors, attributed to their size and shape differences. Overall, the distinct advantages of mini-tablets to provide dose flexibility while maintaining similar release profiles was demonstrated.
Collapse
Affiliation(s)
- Guluzar Gorkem Buyukgoz
- New Jersey Center for Engineered Particulates (NJCEP), New Jersey Institute of Technology, Newark, NJ 07102, USA
- Otto H. York Department of Chemical and Materials Engineering, New Jersey Institute of Technology, Newark, NJ 07102, USA
| | - Christopher G. Kossor
- New Jersey Center for Engineered Particulates (NJCEP), New Jersey Institute of Technology, Newark, NJ 07102, USA
- Otto H. York Department of Chemical and Materials Engineering, New Jersey Institute of Technology, Newark, NJ 07102, USA
| | - Shen Ji
- Otto H. York Department of Chemical and Materials Engineering, New Jersey Institute of Technology, Newark, NJ 07102, USA
| | - Murat Guvendiren
- Otto H. York Department of Chemical and Materials Engineering, New Jersey Institute of Technology, Newark, NJ 07102, USA
| | - Rajesh N. Davé
- New Jersey Center for Engineered Particulates (NJCEP), New Jersey Institute of Technology, Newark, NJ 07102, USA
- Otto H. York Department of Chemical and Materials Engineering, New Jersey Institute of Technology, Newark, NJ 07102, USA
| |
Collapse
|
5
|
Assessment of the Extrusion Process and Printability of Suspension-Type Drug-Loaded Affinisol TM Filaments for 3D Printing. Pharmaceutics 2022; 14:pharmaceutics14040871. [PMID: 35456703 PMCID: PMC9027497 DOI: 10.3390/pharmaceutics14040871] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/26/2022] [Revised: 04/03/2022] [Accepted: 04/13/2022] [Indexed: 02/04/2023] Open
Abstract
Three-dimensional (3D) printing technology enables the design of new drug delivery systems for personalised medicine. Polymers that can be molten are needed to obtain extruded filaments for Fused Deposition Modelling (FDM), one of the most frequently employed techniques for 3D printing. The aim of this work was to evaluate the extrusion process and the physical appearance of filaments made of a hydrophilic polymer and a non-molten model drug. Metformin was used as model drug and Affinisol™ 15LV as the main carrier. Drug-loaded filaments were obtained by using a single-screw extruder and, subsequently, their printability was tested. Blends containing up to a 60% and 50% drug load with 5% and 7.5% of auxiliary excipients, respectively, were successfully extruded. Between the obtained filaments, those containing up to 50% of the drug were suitable for use in FDM 3D printing. The studied parameters, including residence time, flow speed, brittleness, and fractal dimension, reflect a critical point in the extrusion process at between 30-40% drug load. This finding could be essential for understanding the behaviour of filaments containing a non-molten component.
Collapse
|
6
|
Coupling of Fused Deposition Modeling and Inkjet Printing to Produce Drug Loaded 3D Printed Tablets. Pharmaceutics 2022; 14:pharmaceutics14010159. [PMID: 35057054 PMCID: PMC8781861 DOI: 10.3390/pharmaceutics14010159] [Citation(s) in RCA: 7] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/02/2021] [Revised: 01/01/2022] [Accepted: 01/05/2022] [Indexed: 01/30/2023] Open
Abstract
In the current study, we have coupled Fused Deposition Modelling (FDM) for the fabrication of plain polyvinyl alcohol (PVA) tablets followed by dispensing of minoxidil ethanolic solutions using inkjet printing. The use of a drop-on-solid printing approach facilitates an accurate and reproducible process while it controls the deposition of the drug amounts. For the purpose of the study, the effect of the solvent was investigated and minoxidil ink solutions of ethanol 70% v/v (P70) or absolute ethanol (P100) were applied on the plain PVA tablets. Physicochemical characterization showed that solvent miscibility with the polymer substrate plays a key role and can lead to the formation of drug crystals on the surface or drug absorption in the polymer matrix. The produced minoxidil tablets showed sustained release profiles or initial bursts strongly affected by the solvent grade used for dispensing the required dose on drug loaded 3D printed tablets. This paradigm demonstrates that the coupling of FDM and inkjet printing technologies could be used for rapid development of personalized dosage forms.
Collapse
|
7
|
Enhanced Supersaturation via Fusion-Assisted Amorphization during FDM 3D Printing of Crystalline Poorly Soluble Drug Loaded Filaments. Pharmaceutics 2021; 13:pharmaceutics13111857. [PMID: 34834272 PMCID: PMC8618474 DOI: 10.3390/pharmaceutics13111857] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/27/2021] [Revised: 10/30/2021] [Accepted: 11/02/2021] [Indexed: 11/16/2022] Open
Abstract
Filaments loaded with griseofulvin (GF), a model poorly water-soluble drug, were prepared and used for 3D printing via fused deposition modeling (FDM). GF was selected due to its high melting temperature, enabling lower temperature hot-melt extrusion (HME) keeping GF largely crystalline in the filaments, which could help mitigate the disadvantages of high HME processing temperatures such as filament quality, important for printability and the adverse effects of GF recrystallization on tablet properties. Novel aspects include single-step fusion-assisted ASDs generation during FDM 3D printing and examining the impact of tablet surface areas (SA) through printing multi-mini and square-pattern perforated tablets to further enhance drug supersaturation during dissolution. Kollicoat protect and hydroxypropyl cellulose were selected due to their low miscibility with GF, necessary to produce crystalline filaments. The drug solid-state was assessed via XRPD, DSC and FT-IR. At 165 °C HME processing temperature, the filaments containing ~80% crystalline GF were printable. Fusion-assisted 3D printing led to GF supersaturation of ~153% for cylindrical tablets and ~293% with the square-pattern perforated tablets, indicating strong monotonous impact of tablet SA. Dissolution kinetics of drug release profiles indicated Fickian transport for tablets with higher SA, demonstrating greater SA-induced drug supersaturation for well-designed 3D printed tablets.
Collapse
|
8
|
Polymers in pharmaceutical additive manufacturing: A balancing act between printability and product performance. Adv Drug Deliv Rev 2021; 177:113923. [PMID: 34390775 DOI: 10.1016/j.addr.2021.113923] [Citation(s) in RCA: 22] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2021] [Revised: 07/08/2021] [Accepted: 08/09/2021] [Indexed: 12/19/2022]
Abstract
Materials and manufacturing processes share a common purpose of enabling the pharmaceutical product to perform as intended. This review on the role of polymeric materials in additive manufacturing of oral dosage forms, focuses on the interface between the polymer and key stages of the additive manufacturing process, which determine printability. By systematically clarifying and comparing polymer functional roles and properties for a variety of AM technologies, together with current and emerging techniques to characterize these properties, suggestions are provided to stimulate the use of readily available and sometimes underutilized pharmaceutical polymers in additive manufacturing. We point to emerging characterization techniques and digital tools, which can be harnessed to manage existing trade-offs between the role of polymers in printer compatibility versus product performance. In a rapidly evolving technological space, this serves to trigger the continued development of 3D printers to suit a broader variety of polymers for widespread applications of pharmaceutical additive manufacturing.
Collapse
|
9
|
Pharmaceutical Product Modularization as a Mass Customization Strategy to Increase Patient Benefit Cost-Efficiently. SYSTEMS 2021. [DOI: 10.3390/systems9030059] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Customized pharmaceutical products aim to comply with the individual needs of a patient to enhance the treatment outcome. The current pharmaceutical production paradigm is, however, dominated by mass production, where the pharmaceutical products embrace a one-size-fits-all design with a low possibility of treatment optimization to patient needs. This production paradigm is not designed or intended for customized pharmaceutical products and operating this production context for customized pharmaceutical products is argued to be cost-inefficient. To address this challenge of inefficient production of customized pharmaceutical products, this study proposes an approach to modular pharmaceutical product design. As a mass customization strategy, product modularization enables serving customers with customized products cost-efficiently. The proposed modular pharmaceutical products integrate three product design requirements originating from patient needs: a scalable dose strength, a flexible target release profile, and a scalable treatment size. An approach to assess the value of these product designs is presented, by means of proposing three benefit metrics complying with respective design requirements and a cost metric assessing the cost of producing these modular pharmaceutical product designs. Results suggest that pharmaceutical product modularization can, by keeping the number of produced components low, substantially increase the external product variety and, hence, enhance the treatment outcome of patients. Furthermore, results indicate that the achieved benefit for the patient through product modularization increases beyond additional costs arising during production. However, a careful modularization must be performed to optimize the tradeoff between the increased benefit and cost.
Collapse
|
10
|
3D-Printed Mesoporous Carrier System for Delivery of Poorly Soluble Drugs. Pharmaceutics 2021; 13:pharmaceutics13071096. [PMID: 34371787 PMCID: PMC8308994 DOI: 10.3390/pharmaceutics13071096] [Citation(s) in RCA: 15] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2021] [Revised: 07/11/2021] [Accepted: 07/14/2021] [Indexed: 11/17/2022] Open
Abstract
Fused deposition modelling (FDM) is the most extensively employed 3D-printing technique used in pharmaceutical applications, and offers fast and facile formulation development of personalized dosage forms. In the present study, mesoporous materials were incorporated into a thermoplastic filament produced via hot-melt extrusion and used to produce oral dosage forms via FDM. Mesoporous materials are known to be highly effective for the amorphization and stabilization of poorly soluble drugs, and were therefore studied in order to determine their ability to enhance the drug-release properties in 3D-printed tablets. Celecoxib was selected as the model poorly soluble drug, and was loaded into mesoporous silica (MCM-41) or mesoporous magnesium carbonate. In vitro drug release tests showed that the printed tablets produced up to 3.6 and 1.5 times higher drug concentrations, and up to 4.4 and 1.9 times higher release percentages, compared to the crystalline drug or the corresponding plain drug-loaded mesoporous materials, respectively. This novel approach utilizing drug-loaded mesoporous materials in a printed tablet via FDM shows great promise in achieving personalized oral dosage forms for poorly soluble drugs.
Collapse
|
11
|
Govender R, Abrahmsén-Alami S, Folestad S, Olsson M, Larsson A. Enabling modular dosage form concepts for individualized multidrug therapy: Expanding the design window for poorly water-soluble drugs. Int J Pharm 2021; 602:120625. [PMID: 33892062 DOI: 10.1016/j.ijpharm.2021.120625] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2021] [Revised: 04/16/2021] [Accepted: 04/17/2021] [Indexed: 12/13/2022]
Abstract
Multidrug dosage forms (aka combination dosage forms, polypills, etc.) create value for patients through reduced pill burdens and simplified administration to improve adherence to therapy. Enhanced flexibility of multidrug dosage forms would provide further opportunities to better match emerging needs for individualized therapy. Through modular dosage form concepts, one approach to satisfy these needs is to adapt multidrug dosage forms to a wider variety of drugs, each with a variety of doses and release profiles. This study investigates and technically explores design requirements for extending the capability of modular multidrug dosage form concepts towards individualization. This builds on our recent demonstration of independent tailoring of dose and drug release, which is here extended towards poorly water-soluble drugs. The challenging design requirement of carrying higher drug loads in smaller volumes to accommodate multiple drugs at their clinical dose is here met regarding dose and release performance. With a modular concept, we demonstrate high precision (<5% RSD) in dose and release performance of individual modules containing felodipine or naproxen in Kollidon VA64 at both a wide drug loading range (5% w/w and 50% w/w drug) and a small module size (3.6 mg). In a forward-looking design-based discussion, further requirements are addressed, emphasizing that reproducible individual module performance is predictive of dosage form performance, provided the modules are designed to act independently. Therefore, efforts to incorporate progressively higher drug loads within progressively smaller module volumes will be crucial to extend the design window further towards full flexibility of future dosage forms for individualized multidrug therapy.
Collapse
Affiliation(s)
- Rydvikha Govender
- Oral Product Development, Pharmaceutical Technology and Development, Operations, AstraZeneca, SE-43183 Gothenburg, Sweden; Pharmaceutical Technology, Chemistry and Chemical Engineering, Chalmers University of Technology, SE-41296 Gothenburg, Sweden.
| | - Susanna Abrahmsén-Alami
- Oral Product Development, Pharmaceutical Technology and Development, Operations, AstraZeneca, SE-43183 Gothenburg, Sweden
| | - Staffan Folestad
- Innovation Strategies and External Liaison, Pharmaceutical Technology and Development, Operations, AstraZeneca, SE-43183 Gothenburg, Sweden
| | - Martina Olsson
- Department of Physics, Chalmers University of Technology, SE-41296 Gothenburg, Sweden
| | - Anette Larsson
- Pharmaceutical Technology, Chemistry and Chemical Engineering, Chalmers University of Technology, SE-41296 Gothenburg, Sweden
| |
Collapse
|
12
|
Preparation and characterization of hot-melt extruded polycaprolactone-based filaments intended for 3D-printing of tablets. Eur J Pharm Sci 2021; 158:105619. [DOI: 10.1016/j.ejps.2020.105619] [Citation(s) in RCA: 19] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2020] [Revised: 10/04/2020] [Accepted: 10/19/2020] [Indexed: 11/21/2022]
|
13
|
Exploring tablet design options for tailoring drug release and dose via fused deposition modeling (FDM) 3D printing. Int J Pharm 2020; 591:119987. [DOI: 10.1016/j.ijpharm.2020.119987] [Citation(s) in RCA: 22] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/08/2020] [Revised: 09/25/2020] [Accepted: 10/11/2020] [Indexed: 01/22/2023]
|
14
|
Govender R, Abrahmsén-Alami S, Larsson A, Borde A, Liljeblad A, Folestad S. Independent Tailoring of Dose and Drug Release via a Modularized Product Design Concept for Mass Customization. Pharmaceutics 2020; 12:E771. [PMID: 32823877 PMCID: PMC7465528 DOI: 10.3390/pharmaceutics12080771] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/21/2020] [Revised: 08/11/2020] [Accepted: 08/12/2020] [Indexed: 12/15/2022] Open
Abstract
Independent individualization of multiple product attributes, such as dose and drug release, is a crucial overarching requirement of pharmaceutical products for individualized therapy as is the unified integration of individualized product design with the processes and production that drive patient access to such therapy. Individualization intrinsically demands a marked increase in the number of product variants to suit smaller, more stratified patient populations. One established design strategy to provide enhanced product variety is product modularization. Despite existing customized and/or modular product design concepts, multifunctional individualization in an integrated manner is still strikingly absent in pharma. Consequently, this study aims to demonstrate multifunctional individualization through a modular product design capable of providing an increased variety of release profiles independent of dose and dosage form size. To further exhibit that increased product variety is attainable even with a low degree of product modularity, the modular design was based upon a fixed target dosage form size of approximately 200 mm3 comprising two modules, approximately 100 mm3 each. Each module contained a melt-extruded and molded formulation of 40% w/w metoprolol succinate in a PEG1500 and Kollidon® VA64 erodible hydrophilic matrix surrounded by polylactic acid and/or polyvinyl acetate as additional release rate-controlling polymers. Drug release testing confirmed the generation of predictable, combined drug release kinetics for dosage forms, independent of dose, based on a product's constituent modules and enhanced product variety through a minimum of six dosage form release profiles from only three module variants. Based on these initial results, the potential of the reconfigurable modular product design concept is discussed for unified integration into a pharmaceutical mass customization/mass personalization context.
Collapse
Affiliation(s)
- Rydvikha Govender
- Oral Product Development, Pharmaceutical Technology and Development, Operations, AstraZeneca, SE-43183 Gothenburg, Sweden; (S.A.-A.); (A.B.); (A.L.)
- Pharmaceutical Technology, Chemistry and Chemical Engineering, Chalmers University of Technology, SE-41296 Gothenburg, Sweden;
| | - Susanna Abrahmsén-Alami
- Oral Product Development, Pharmaceutical Technology and Development, Operations, AstraZeneca, SE-43183 Gothenburg, Sweden; (S.A.-A.); (A.B.); (A.L.)
| | - Anette Larsson
- Pharmaceutical Technology, Chemistry and Chemical Engineering, Chalmers University of Technology, SE-41296 Gothenburg, Sweden;
| | - Anders Borde
- Oral Product Development, Pharmaceutical Technology and Development, Operations, AstraZeneca, SE-43183 Gothenburg, Sweden; (S.A.-A.); (A.B.); (A.L.)
| | - Alexander Liljeblad
- Oral Product Development, Pharmaceutical Technology and Development, Operations, AstraZeneca, SE-43183 Gothenburg, Sweden; (S.A.-A.); (A.B.); (A.L.)
| | - Staffan Folestad
- Innovation Strategies and External Liaison, Pharmaceutical Technology and Development, Operations, AstraZeneca, SE-43183 Gothenburg, Sweden;
| |
Collapse
|